CANY
RGNX icon

Caxton Associates (New York)’s Regenxbio RGNX Stock Holding History

Caxton Associates (New York)’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,637
Closed -$122K – 648
2024
Q3 		$122K Buy
+11,637
New +$142K ﹤0.01% 503

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caxton Associates (New York)'s RGNX Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Regenxbio (RGNX) in Q4 2024, closing a stake of 11,637 shares — an estimated $122K sold.

Caxton Associates (New York) first reported a position in RGNX in Q3 2024 and held it in 1 quarter. The position peaked at $122K in Q3 2024. 177 funds tracked by Wall St. Rank hold RGNX as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Regenxbio position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 11,637 Regenxbio shares in Q4 2024, an estimated $122K.
  • Caxton Associates (New York) first reported a position in Regenxbio in Q3 2024 and held it in 1 quarter.
  • Caxton Associates (New York)'s Regenxbio position peaked at $122K in Q3 2024.
  • 177 funds tracked by Wall St. Rank held Regenxbio as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.